Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations

Journal of Psychiatric Practice

Volumn 13, Issue 3, 2007, Pages 170-177

  Daniel, David G ^a,g   Currier, Glenn W ^b   Zimbroff, Dan L ^c   Allen, Michael H ^d   Oren, Dan ^e   Manos, George ^e   McQuade, Robert ^f   Pikalov, Andrei A ^f   Crandall, David T ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Pacific Clinical Research Medical Group   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^g NONE   (United States)

Author keywords

Agitation; Aripiprazole; Behavioral emergencies; Haloperidol; Intramuscular; Oral; Schizophrenia; Transition

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PLACEBO;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA;

EID: 34249306913     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000271658.86845.81     Document Type: Article

References (41)

1. Currier GW, Chou JCY, Feifel D. Acute treatment of psychotic agitation: A randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65:386-94.
2. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006;12:30-40.
3. Allen MH, Currier GW, Carpenter D, et al. Expert consensus guideline series: Treatment of behavioral emergencies, 2005. J Psychiatr Pract 2005;11(suppl 1):1-108.
4. Stimmel GL. Benzodiazepines in schizophrenia. Pharmacotherapy 1996;16:148S-51S; discussion 166S-8S.
5. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;61:339-46.
6. Allen MH. Managing the agitated psychotic patients: A reappraisal of the evidence. J Clin Psychiatry 2000;61:11-20.
7. Battaglia J. Pharmacological management of acute agitation. Drugs 2005;66:1207-22.
8. McAllister-Williams RH, Ferrier IN. Rapid tranquillisation; Time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002;180:485-9.
9. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
10. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled, dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
11. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: Antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003;48:716-21.
12. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry 2000;61:933-41.
13. Daniel DJ, Potkin SG, Reeves K, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology 2001;155:128-34.
14. Zimbroff D, Oren DA, Marcus R, et al. Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171-6.
15. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007:68;111-9.
16. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo controlled comparison with haloperidol. Psychopharmacology 2006;188:281-92.
17. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16:145-54.
18. San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. Curr Pharm Des 2005;11:2471-7.
19. Zimbroff D. Management of acute psychosis: From emergency to stabilization. CNS Spectr 2003;8(11 suppl 2):10-5.
20. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8.
21. Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004;19:9-15.
22. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely ill patients diagnosed with bipolar mania. J Clin Psychiatry 2001;21:389-97.
23. Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420-8.
24. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
25. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
26. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
27. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia and schizoaffective disorder. J Clin Psychiatry 2003;64:1048-56.
28. Harrison TS, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
29. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005;187:235-42.
30. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar 1 disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-46.
31. Keck PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
32. Keck PE, Calbrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar 1 disorder. J Clin Psychiatry 2006;67:626-37.
33. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
34. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study. J Clin Psychiatry 2004;65:47-56.
35. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 218-22.
36. Meehan, KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
37. Corrigan JD. Development of a scale for assessment of agitation following traumatic brain injury. J Clin Exp Neuropsychol 1989;11:261-77.
38. Brook S,Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178: 514-23.
39. Kadouri A, Corruble E, Falissard B. The improved clinical global impression scale (iCGI): Development and validation in depression. BMC Psychiatry 2007;7:1-7.
40. Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study. CMRO 2006;22:2209-19.
41. Jann MW. Clinical significance of drug binding, protein binding and binding displacement drug interactions. Psychopharmacol Bull 2002;36:22-41.